TY - JOUR T1 - Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection JF - medRxiv DO - 10.1101/2021.12.13.21267611 SP - 2021.12.13.21267611 AU - Shmuel Shoham AU - Evan M Bloch AU - Arturo Casadevall AU - Daniel Hanley AU - Bryan Lau AU - Kelly Gebo AU - Edward Cachay AU - Seble G. Kassaye AU - James H. Paxton AU - Jonathan Gerber AU - Adam C Levine AU - Judith Currier AU - Bela Patel AU - Elizabeth S. Allen AU - Shweta Anjan AU - Lawrence Appel AU - Sheriza Baksh AU - Paul W. Blair AU - Anthony Bowen AU - Patrick Broderick AU - Christopher A Caputo AU - Valerie Cluzet AU - Marie Elena Cordisco AU - Daniel Cruser AU - Stephan Ehrhardt AU - Donald Forthal AU - Yuriko Fukuta AU - Amy L. Gawad AU - Thomas Gniadek AU - Jean Hammel AU - Moises A. Huaman AU - Douglas A. Jabs AU - Anne Jedlicka AU - Nicky Karlen AU - Sabra Klein AU - Oliver Laeyendecker AU - Karen Lane AU - Nichol McBee AU - Barry Meisenberg AU - Christian Merlo AU - Giselle Mosnaim AU - Han-Sol Park AU - Andrew Pekosz AU - Joann Petrini AU - William Rausch AU - David M. Shade AU - Janna R. Shapiro AU - J. Robinson Singleton AU - Catherine Sutcliffe AU - David L. Thomas AU - Anusha Yarava AU - Martin Zand AU - Jonathan M. Zenilman AU - Aaron A.R. Tobian AU - David Sullivan Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267611.abstract N2 - BACKGROUND The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent infection when administered before symptoms or laboratory evidence of infection.METHODS This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed COVID-19 in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was development of SARS-CoV-2 infection.RESULTS 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for SARS-CoV-2 RT-PCR positivity at screening. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. There were 28 adverse events in CCP and 58 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs. 25.2 days; p=0.49) and COVID-19 (26.3 vs. 25.9 days; p=0.35) were similar for both groups.CONCLUSION In this trial, which enrolled persons with recent exposure to a person with confirmed COVID-19, high titer CCP as post-exposure prophylaxis appeared safe, but did not prevent SARS-CoV-2 infection.Trial Registration Clinicaltrial.gov number NCT04323800.Competing Interest StatementDr. Cachay: Research funding: Gilead Science, Merck Sharp & Dohme, Dr. Shoham: Research funding: Ansun, Merck, Gilead, Emergent Biosultions; DSMB: Adamis, Karyopharm, Intermountain Health; consulting: Celltrion, Adagio, Immunone, Jannssen, Clinical TrialNCT04323800.Funding StatementThis study was funded principally by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1, NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098, Mental Wellness Foundation, Moriah Fund, Octapharma, HealthNetwork Foundation and the Shear Family Foundation The study sponsors did not contribute to the study design; the collection, analysis, and interpretation of data; manuscript preparation, and the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Institutional Review Boards at Johns Hopkins University School of Medicine functioning as single IRB for all participating sites. An independent data and safety monitoring board provided oversight and reviewed efficacy and safety as the study was conducted. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -